

IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1-27. (Cancelled)

28. (Currently Amended) A transdermal therapeutic system comprising a drug-containing adhesive matrix, ~~in which the drug is rotigotine free-base~~, wherein the drug-containing adhesive matrix ~~contains~~ comprises:

rotigotine free-base and

hot-melttable adhesive, ~~the hot-melttable adhesive consisting of one adhesive or a mixture of different adhesives or of a mixture of an adhesive and a softener, and~~

wherein the drug-containing adhesive matrix is produced by metering rotigotine free-base into a solvent-free melt at a temperature of between 70°C and 200°C, and

wherein the drug-containing adhesive matrix exhibits ~~exhibiting~~ at 160°C a dynamic viscosity of not more than 100 Pa.s.

29. (Previously Presented) The transdermal therapeutic system of claim 28 wherein the rotigotine free-base is dispersed or partly or completely dissolved in said hot-melttable adhesive.

30. (Currently Amended) The transdermal therapeutic system of claim 28 wherein the drug-containing adhesive matrix is produced by metering the rotigotine free-base into the solvent-free melt ~~of the adhesive matrix~~ at a temperature of between 120°C and 160°C.

31. (Previously Presented) The transdermal therapeutic system of claim 28 wherein the hot-melttable adhesive consists of a mixture of an amine-resistant silicone adhesive and at least one suitable softener.

32. (Previously Presented) The transdermal therapeutic system of claim 31 wherein the softener is an organic wax.

33. (Previously Presented) The transdermal therapeutic system of claim 31 wherein the softener is ceresine or ozokerite.

34. (Previously Presented) The transdermal therapeutic system of claim 28 wherein the proportion of rotigotine free-base in the adhesive layer is 4 to 40 weight %.

35. (Previously Presented) The transdermal therapeutic system of claim 28 wherein the proportion of rotigotine free-base in the adhesive layer is 9 to 30 weight %.

36. (Previously Presented) The transdermal therapeutic system of claim 28 wherein the proportion of rotigotine free-base in the adhesive layer is 20 to 40 weight %.

37. (Cancelled)

38. (Withdrawn) The transdermal therapeutic system of claim 28 wherein the drug-containing adhesive matrix additionally contains an internal-phase component selected from the group consisting of

- (a) hydrophilic and amphiphilic polymers;
- (b) hydrophilic and amphiphilic copolymers;
- (c) mixtures of (a) and/or (b) with pharmaceutically acceptable softeners;
- (d) condensates from glycerin and fatty acids or polyols; and
- (e) suitable mixtures of the components (a)-(d).

39. (Withdrawn) The transdermal therapeutic system of claim 38 wherein the internal-phase component is selected from the group consisting of polysaccharides, substituted polysaccharides, polyethylene oxides, polyvinyl acetates, polyvinyl pyrrolidones, copolymers

from polyvinyl pyrrolidone and (poly)vinyl acetate, polyethylene glycol, polypropylene glycol, copolymers from ethylene and vinyl acetate, glycerin-fatty acid esters and mixtures of polyvinyl alcohol with glycerin.

40. (Withdrawn) The transdermal therapeutic system of claim 28 wherein the adhesive matrix comprises:

- (a) 50-99 weight % of said hot-melttable adhesive;
- (b) 4-40 weight % rotigotine in the base form;
- (c) 0-40 weight % of an internal-phase component; and
- (d) 0-10 weight % of other adjuvants.

41. (Original) The transdermal therapeutic system of claim 28 wherein the hot-melttable adhesive is

- (a1) an EVA adhesive,
- (a2) an SxS adhesive, or
- (a3) a mixture of
 - (i) 70-99 weight % of an amine-resistant silicone adhesive and
 - (ii) 1-30 weight % of a suitable softener.

42-44. (Cancelled)

45. (Withdrawn) A transdermal therapeutic system for administration of rotigotine, comprising: a layer that comprises rotigotine, wherein the layer

- (a) contains rotigotine in a percentile proportion of at least 20 weight %,
- (b) has a rotigotine content of at least 2.0 mg/cm², and
- (c) optionally contains an organic wax and/or internal-phase component in an amount sufficient to retard the release of rotigotine.

46. (Withdrawn) The transdermal therapeutic system of claim 45 wherein rotigotine is transported through the skin at a steady-state flux rate of 100-500 μg per hour over a period of at least 5 days.

47. (Withdrawn) The transdermal therapeutic system of claim 45 wherein rotigotine is transported through the human skin at a flux rate of 100-500 μg per hour over a period of at least 7 days.

48. (Withdrawn) The transdermal therapeutic system of claim 45 wherein the system induces in the patient an average plasma concentration of 0.4 to 2 ng/ml rotigotine for a period of at least 5 days.

49-51. (Cancelled)

52. (Withdrawn) A method for producing a transdermal therapeutic system that encompasses an adhesive matrix comprising rotigotine, the method comprising: prior to lamination, components of the adhesive matrix are melted and homogenized, solvent-free, at temperatures of between 70°C and 200°C.

53. (Withdrawn) The method of claim 52 wherein components of the adhesive matrix are melted and homogenized in an extruder.

54. (Withdrawn) The method of claim 52 wherein the hot-melting process takes place at temperatures between 120°C and 160°C.

55. (Withdrawn) The method of claim 52 wherein rotigotine is introduced, in the adhesive matrix melt, in its solid state.

Serial No. 10/523,908

6102-000075/US/NP

Amendment D, Response to office action dated 9 December 2009 and Supp. IDS

31 March 2010

56. (Withdrawn) The method of claim 52 wherein the adhesive matrix, produced by the hot-melting process, contains rotigotine at a purity level of at least 98% as measured by HPLC at 220 nm and 272 nm.

57-59. (Cancelled)